| NCT ID | NCT05979675 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Turkish Hematology Association |
| Condition | Acute Myeloid Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2021-12-21 |
| Primary Completion | 2026-12-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2021-12-21 with a primary completion date of 2026-12-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Eligibility Criteria
Inclusion Criteria: * Diagnosed as AML after 1 Jan 2020 * Patients signed informed consent form Exclusion Criteria: * Patients under 18 years old
Contact & Investigator
Ilker Kurkcu
STUDY DIRECTOR
Sentez Cro
Frequently Asked Questions
Who can join the NCT05979675 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05979675 currently recruiting?
Yes, NCT05979675 is actively recruiting participants. Contact the research team at dr_v_karakus@yahoo.com for enrollment information.
Where is the NCT05979675 trial being conducted?
This trial is being conducted at Antalya, Turkey (Türkiye).
Who is sponsoring the NCT05979675 clinical trial?
NCT05979675 is sponsored by Turkish Hematology Association. The principal investigator is Ilker Kurkcu at Sentez Cro. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.